title: [Bevacizumab for the treatment of cerebral radionecrosis].
abstract: Bevacizumab is a monoclonal antibody, which neutralizes the effect of vascular endothelium growth factor (VEGF) allowing regression of tumour vessels and a decrease in the permeability of the blood-brain barrier. Already used in oncology as adjuvant treatment for certain metastatic cancers and in second line for high-grade gliomas, it has been recently used as a treatment of cerebral radionecrosis resisting conventional drug treatment and hyperbaric oxygen. This article presents three patients with cerebral radionecrosis and treated by monthly infusions of bevacizumab (10 mg/kg per month). The patients had developed cerebral radionecrosis after radiation therapy for a malignant brain tumour. The radionecrosis was proved by magnetic resonance imaging and spectroscopy. The first patient received only one perfusion of bevacizumab, as the development of a lymphopenia prevented the patient from continuing with the treatment. The second patient received four infusions, but the absence of improvement of the clinical symptoms and progression of the radiolesion led to discontinuation of the treatment. The third patient developed several severe side effects, a transient ischemic accident and a perforated corneal ulcer, resulting again in premature discontinuation of treatment. The development of severe side effects, combined with the absence of notable clinical and radiologic improvements resulting from the use of bevacizumab as a treatment resulted in the premature interruption of such treatment, in all three patients.
authors.affiliation: Service de neurologie, hôpital Pasteur, 30, voie Romaine, 06002 Nice cedex, France.
authors.forename: S
authors.initials: S
authors.lastname: Gronier
authors.forename: V
authors.initials: V
authors.lastname: Bourg
authors.forename: M
authors.initials: M
authors.lastname: Frenay
authors.forename: M
authors.initials: M
authors.lastname: Cohen
authors.forename: L
authors.initials: L
authors.lastname: Mondot
authors.forename: P
authors.initials: P
authors.lastname: Thomas
authors.forename: C
authors.initials: C
authors.lastname: Lebrun
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001927:Brain Diseases / Q000188:drug therapy* / Q000473:pathology; D001932:Brain Neoplasms / Q000150:complications / Q000532:radiotherapy; D003320:Corneal Ulcer / Q000209:etiology; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000209:etiology; D008175:Lung Neoplasms / Q000532:radiotherapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000188:drug therapy; D016634:Radiosurgery; D011878:Radiotherapy / Q000009:adverse effects*; D020521:Stroke / Q000209:etiology / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab